Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
LNTH vs RMD vs BWXT vs MDT vs CCJ
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Aerospace & Defense
Medical - Devices
Uranium
LNTH vs RMD vs BWXT vs MDT vs CCJ — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Instruments & Supplies | Aerospace & Defense | Medical - Devices | Uranium |
| Market Cap | $5.92B | $30.15B | $19.22B | $99.94B | $51.67B |
| Revenue (TTM) | $1.55B | $5.54B | $3.38B | $35.48B | $3.48B |
| Net Income (TTM) | $279M | $1.52B | $345M | $4.61B | $589M |
| Gross Margin | 60.5% | 61.7% | 16.8% | 61.9% | 29.4% |
| Operating Margin | 18.8% | 34.3% | 11.0% | 17.9% | 17.5% |
| Forward P/E | 17.5x | 18.8x | 45.5x | 14.1x | 74.0x |
| Total Debt | $738K | $852M | $2.02B | $28.52B | $1.02B |
| Cash & Equiv. | $359M | $1.21B | $503M | $2.22B | $1.11B |
LNTH vs RMD vs BWXT vs MDT vs CCJ — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Lantheus Holdings, … (LNTH) | 100 | 662.8 | +562.8% |
| ResMed Inc. (RMD) | 100 | 128.7 | +28.7% |
| BWX Technologies, I… (BWXT) | 100 | 335.3 | +235.3% |
| Medtronic plc (MDT) | 100 | 79.1 | -20.9% |
| Cameco Corporation (CCJ) | 100 | 1091.6 | +991.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LNTH vs RMD vs BWXT vs MDT vs CCJ
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LNTH is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 41.9% 10Y total return vs CCJ's 9.3%
- Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
RMD is the #2 pick in this set and the best alternative if valuation efficiency and defensive is your priority.
- PEG 1.08 vs MDT's 36.00
- Beta 0.66, yield 1.0%, current ratio 3.44x
- Lower P/E (18.8x vs 74.0x)
- 27.4% margin vs BWXT's 10.2%
BWXT ranks third and is worth considering specifically for growth.
- 18.3% revenue growth vs LNTH's 0.5%
MDT carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Beta 0.47 vs CCJ's 1.72
- 3.6% yield, 36-year raise streak, vs CCJ's 0.1%, (1 stock pays no dividend)
- 175.8% ROA vs CCJ's 6.0%, ROIC 6.0% vs 6.3%
CCJ is the clearest fit if your priority is growth exposure.
- Rev growth 10.9%, EPS growth 246.2%, 3Y rev CAGR 23.0%
- +138.9% vs RMD's -14.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.3% revenue growth vs LNTH's 0.5% | |
| Value | Lower P/E (18.8x vs 74.0x) | |
| Quality / Margins | 27.4% margin vs BWXT's 10.2% | |
| Stability / Safety | Beta 0.47 vs CCJ's 1.72 | |
| Dividends | 3.6% yield, 36-year raise streak, vs CCJ's 0.1%, (1 stock pays no dividend) | |
| Momentum (1Y) | +138.9% vs RMD's -14.5% | |
| Efficiency (ROA) | 175.8% ROA vs CCJ's 6.0%, ROIC 6.0% vs 6.3% |
LNTH vs RMD vs BWXT vs MDT vs CCJ — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
LNTH vs RMD vs BWXT vs MDT vs CCJ — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MDT leads in 2 of 6 categories
RMD leads 1 • LNTH leads 1 • CCJ leads 1 • BWXT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
RMD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 22.9x LNTH's $1.5B. RMD is the more profitable business, keeping 27.4% of every revenue dollar as net income compared to BWXT's 10.2%. On growth, BWXT holds the edge at +26.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.5B | $5.5B | $3.4B | $35.5B | $3.5B |
| EBITDAEarnings before interest/tax | $347M | $2.1B | $458M | $9.4B | $912M |
| Net IncomeAfter-tax profit | $279M | $1.5B | $345M | $4.6B | $589M |
| Free Cash FlowCash after capex | $372M | $1.8B | $328M | $5.4B | $1.1B |
| Gross MarginGross profit ÷ Revenue | +60.5% | +61.7% | +16.8% | +61.9% | +29.4% |
| Operating MarginEBIT ÷ Revenue | +18.8% | +34.3% | +11.0% | +17.9% | +17.5% |
| Net MarginNet income ÷ Revenue | +18.0% | +27.4% | +10.2% | +13.0% | +16.9% |
| FCF MarginFCF ÷ Revenue | +24.0% | +31.7% | +9.7% | +15.2% | +30.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.2% | +10.8% | +26.1% | +8.8% | +1.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +76.5% | +9.3% | +20.7% | -11.9% | +45.2% |
Valuation Metrics
MDT leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 82% valuation discount to CCJ's 119.9x P/E. Adjusting for growth (PEG ratio), RMD offers better value at 1.25x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $5.9B | $30.1B | $19.2B | $99.9B | $51.7B |
| Enterprise ValueMkt cap + debt − cash | $5.6B | $29.8B | $20.7B | $126.2B | $51.6B |
| Trailing P/EPrice ÷ TTM EPS | 26.69x | 21.76x | 58.43x | 21.60x | 119.93x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.52x | 18.78x | 45.51x | 14.13x | 74.01x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.25x | 13.62x | 36.00x | — |
| EV / EBITDAEnterprise value multiple | 14.61x | 15.51x | 47.94x | 14.32x | 79.53x |
| Price / SalesMarket cap ÷ Revenue | 3.84x | 5.86x | 6.01x | 2.98x | 20.26x |
| Price / BookPrice ÷ Book value/share | 5.72x | 5.11x | 15.62x | 2.08x | 10.22x |
| Price / FCFMarket cap ÷ FCF | 16.73x | 18.14x | 65.08x | 19.28x | 68.99x |
Profitability & Efficiency
LNTH leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
BWXT delivers a 27.9% return on equity — every $100 of shareholder capital generates $28 in annual profit, vs $9 for CCJ. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to BWXT's 1.63x. On the Piotroski fundamental quality scale (0–9), RMD scores 8/9 vs BWXT's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +24.3% | +24.4% | +27.9% | +9.4% | +8.8% |
| ROA (TTM)Return on assets | +12.4% | +18.0% | +8.6% | +175.8% | +6.0% |
| ROICReturn on invested capital | +30.6% | +22.8% | +10.1% | +6.0% | +6.3% |
| ROCEReturn on capital employed | +17.1% | +25.7% | +10.8% | +7.5% | +6.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 8 | 5 | 6 | 8 |
| Debt / EquityFinancial leverage | 0.00x | 0.14x | 1.63x | 0.59x | 0.15x |
| Net DebtTotal debt minus cash | -$358M | -$358M | $1.5B | $26.3B | -$92M |
| Cash & Equiv.Liquid assets | $359M | $1.2B | $503M | $2.2B | $1.1B |
| Total DebtShort + long-term debt | $738,000 | $852M | $2.0B | $28.5B | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | 11.72x | 66.06x | 10.88x | 9.08x | 10.04x |
Total Returns (Dividends Reinvested)
CCJ leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CCJ five years ago would be worth $59,356 today (with dividends reinvested), compared to $7,230 for MDT. Over the past 12 months, CCJ leads with a +138.9% total return vs RMD's -14.5%. The 3-year compound annual growth rate (CAGR) favors CCJ at 63.0% vs RMD's -2.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +35.3% | -15.2% | +15.5% | -18.1% | +20.4% |
| 1-Year ReturnPast 12 months | +13.1% | -14.5% | +95.6% | -2.8% | +138.9% |
| 3-Year ReturnCumulative with dividends | -4.0% | -8.4% | +226.8% | -4.2% | +333.3% |
| 5-Year ReturnCumulative with dividends | +314.2% | +11.0% | +224.9% | -27.7% | +493.6% |
| 10-Year ReturnCumulative with dividends | +4192.5% | +293.8% | +551.5% | +26.5% | +934.7% |
| CAGR (3Y)Annualised 3-year return | -1.4% | -2.9% | +48.4% | -1.4% | +63.0% |
Risk & Volatility
Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than CCJ's 1.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs RMD's 70.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.47x | 0.66x | 1.60x | 0.47x | 1.72x |
| 52-Week HighHighest price in past year | $93.00 | $293.81 | $241.82 | $106.33 | $135.24 |
| 52-Week LowLowest price in past year | $47.25 | $198.64 | $105.07 | $77.16 | $47.87 |
| % of 52W HighCurrent price vs 52-week peak | +97.8% | +70.4% | +86.8% | +73.3% | +87.7% |
| RSI (14)Momentum oscillator 0–100 | 61.2 | 35.6 | 48.5 | 27.3 | 56.1 |
| Avg Volume (50D)Average daily shares traded | 886K | 1.1M | 1.0M | 7.8M | 3.2M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: LNTH as "Buy", RMD as "Buy", BWXT as "Buy", MDT as "Buy", CCJ as "Buy". Consensus price targets imply 40.5% upside for MDT (target: $110) vs 0.1% for BWXT (target: $210). For income investors, MDT offers the higher dividend yield at 3.57% vs CCJ's 0.15%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $101.00 | $281.29 | $210.00 | $109.50 | $125.91 |
| # AnalystsCovering analysts | 17 | 35 | 16 | 49 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | +1.0% | +0.5% | +3.6% | +0.1% |
| Dividend StreakConsecutive years of raises | 0 | 14 | 10 | 36 | 2 |
| Dividend / ShareAnnual DPS | — | $2.11 | $1.01 | $2.78 | $0.24 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.1% | +1.0% | +0.2% | +3.2% | 0.0% |
MDT leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). RMD leads in 1 (Income & Cash Flow). 1 tied.
LNTH vs RMD vs BWXT vs MDT vs CCJ: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is LNTH or RMD or BWXT or MDT or CCJ a better buy right now?
For growth investors, BWX Technologies, Inc.
(BWXT) is the stronger pick with 18. 3% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — LNTH or RMD or BWXT or MDT or CCJ?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Cameco Corporation at 119. 9x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 08x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — LNTH or RMD or BWXT or MDT or CCJ?
Over the past 5 years, Cameco Corporation (CCJ) delivered a total return of +493.
6%, compared to -27. 7% for Medtronic plc (MDT). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus MDT's +26. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — LNTH or RMD or BWXT or MDT or CCJ?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
47β versus Cameco Corporation's 1. 72β — meaning CCJ is approximately 268% more volatile than MDT relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 163% for BWX Technologies, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — LNTH or RMD or BWXT or MDT or CCJ?
By revenue growth (latest reported year), BWX Technologies, Inc.
(BWXT) is pulling ahead at 18. 3% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Cameco Corporation grew EPS 246. 2% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, CCJ leads at 23. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — LNTH or RMD or BWXT or MDT or CCJ?
ResMed Inc.
(RMD) is the more profitable company, earning 27. 2% net margin versus 10. 3% for BWX Technologies, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus 10. 1% for BWXT. At the gross margin level — before operating expenses — MDT leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is LNTH or RMD or BWXT or MDT or CCJ more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 08x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 74. 0x for Cameco Corporation — 59. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDT: 40. 5% to $109. 50.
08Which pays a better dividend — LNTH or RMD or BWXT or MDT or CCJ?
In this comparison, MDT (3.
6% yield), RMD (1. 0% yield), BWXT (0. 5% yield), CCJ (0. 1% yield) pay a dividend. LNTH does not pay a meaningful dividend and should not be held primarily for income.
09Is LNTH or RMD or BWXT or MDT or CCJ better for a retirement portfolio?
For long-horizon retirement investors, ResMed Inc.
(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +293. 8% 10Y return). BWX Technologies, Inc. (BWXT) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RMD: +293. 8%, BWXT: +551. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between LNTH and RMD and BWXT and MDT and CCJ?
These companies operate in different sectors (LNTH (Healthcare) and RMD (Healthcare) and BWXT (Industrials) and MDT (Healthcare) and CCJ (Energy)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: LNTH is a small-cap quality compounder stock; RMD is a mid-cap quality compounder stock; BWXT is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock; CCJ is a mid-cap quality compounder stock. RMD, MDT pay a dividend while LNTH, BWXT, CCJ do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.